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ABSTRACT
Profilin 1 (Pfn1), a regulator of actin polymerization, controls cell movement in a context-dependent manner. Pfn1 supports the
locomotion of most adherent cells by assisting actin-filament elongation, as has been shown in skeletal progenitor cells in our
previous study. However, because Pfn1 has also been known to inhibit migration of certain cells, including T cells, by suppressing
branched-end elongation of actin filaments, we hypothesized that its roles in osteoclasts may be different from that of osteoblasts.
By investigating the osteoclasts in culture, we first verified that Pfn1-knockdown (KD) enhances bone resorption in preosteoclastic
RAW264.7 cells, despite having a comparable number and size of osteoclasts. Pfn1-KD in bone marrow cells showed similar results.
Mechanistically, Pfn1-KD osteoclasts appeared more mobile than in controls. In vivo, the osteoclast-specific conditional Pfn1-
deficient mice (Pfn1-cKO) by CathepsinK-Cre driver demonstrated postnatal skeletal phenotype, including dwarfism, craniofacial
deformities, and long-bone metaphyseal osteolytic expansion, by 8 weeks of age. Metaphyseal and diaphyseal femurs were
drastically expanded with suppressed trabecular bone mass as indicated by mCT analysis. Histologically, TRAP-positive osteoclasts
were increased at endosteal metaphysis to diaphysis of Pfn1-cKO mice. The enhanced movement of Pfn1-cKO osteoclasts in culture
was associated with a slight increase in cell size and podosome belt length, as well as an increase in bone-resorbing activity. Our
study, for the first time, demonstrated that Pfn1 has critical roles in inhibiting osteoclast motility and bone resorption, thereby
contributing to essential roles in postnatal skeletal homeostasis. Our study also provides novel insight into understanding skeletal
deformities in human disorders. © 2018 American Society for Bone and Mineral Research.
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Introduction
Skeletal homeostasis is maintained by various factors,including hormones, cytokines, growth factors, and coupling
factors.(1,2) Those factors influence cell–cell communication,
signaling, gene expression, and behaviors including division,
proliferation, vesicular transportation, and migration. By
focusing on skeletal cell movement in growing mice,(3–6) we
previously demonstrated that profilin1 (Pfn1), one of the major
modulators of actin cytoskeleton, plays important roles during
skeletogenesis and bone homeostasis.(5–7) The conditional
Pfn1-deficient mice in limb mesenchyme had a failure in
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chest-wall closure and endochondral ossification in long
bones.(5) Conditional Pfn1 deficiency in osteocytes resulted in
impaired osteocytic dendrite formation and bone mass
maintenance,(6) consistent with the idea that Pfn1 enhances
the movement of most mesenchymal cells by supporting the
elongation of straight actin filaments assisted by formin.
However, pfn1 functions in modulating actin-filament
elongation are known to be controversial, depending on the
cell-type or cell-context difference.(8) In epithelial and cancer
cells, Pfn1 is known to inhibit their movement,(9) possibly
through inhibiting branched-end actin filaments(10–12) that are
necessary for structuring lamellipodia, podosomes, and inva-
dopodias. Invadopodia is a podosome-like process in cancer
cells; thus, Pfn1-deficient breast cancer cells are more invasive.(9)
Similarly, Pfn1-deficient cytotoxic T cells are more active in
movement and cancer-killing functions than are Pfn1-positive
cells.(13)
Osteoclasts are critical players in bone remodeling and belong
to the macrophage lineage cells. Their differentiation and
activation requires cell–cell fusion, vesicle trafficking, trans-
cytosis, and sealing zone formation, etc.—all of which require
cytoskeletal reorganization.(14,15) Characteristically, the osteo-
clasts utilize a cellular process, named podosome, with specific
arrangements for their movement or attachment, depending on
the differentiation/activation status.(16) Most characteristically,
the activated osteoclasts at the terminal differentiation stage
create the structure, the podosome belt, which is required for
active bone resorption. Because the core structures of
podosome and lamellipodia are postulated to be negatively
regulated by Pfn1, it is of interest to test if the inhibition of Pfn1 in
osteoclasts leads to increased cellular movement and to related
behavior based on cytoskeletal changes.
Therefore, in this study, we investigated the Pfn1 function in
osteoclasts by utilizing the preosteoclastic cell line and mice
deficient for Pfn1, specifically in osteoclasts. By analyzing the
phenotypic manifestations of mutant mice, we revealed
the critical functions of Pfn1 in suppressing osteoclast movement
and bone resorptive activity. In addition, we propose that
observed skeletal phenotypes in these model mice might be
related to thepathogenesis of certain osteolytic disorders that are
possibly influenced by the modulation of the actin cytoskeleton.
Materials and Methods
Animals
Pfn1-floxed (Pfn1fl/fl) mice were generated previously.(7) To
obtain conditional mutant mice lacking Pfn1 in mature
osteoclasts, Pfn1fl/fl mice were crossed with Cathepsin K
(CatK)-Cre knocked-in mice.(17) Progenies were genotyped by
genomic PCR. The neonatal, adolescent, and adult littermates
were analyzed for the skeletal phenotypes at postnatal day 0
(p0), 4 weeks, and 8 weeks. Mice were housed under controlled
conditions at 24°C on a 12-hour light and 12-hour dark cycle. All
the experiments were approved by the animal welfare
committee of TokyoMedical and Dental University (#0170041A).
Radiological analysis
A skeletal soft X-ray radiogram of each animal was captured
under anesthesia at 40 kV, 12mA for 5 s, using Softex apparatus
(Softex Japan Co., Kobe, Japan). Three-dimensional mCT images
were obtained using the Scan-Xmate-E090 (Comscan Tecno,
Sagamihara, Japan). The morphometric trabecular bone
parameters such as bone volume/tissue volume (BV/TV),
trabecular number (Tb.N), trabecular thickness (Tb.Th), trabecu-
lar spacing (Tb.Spac), and trabecular separation (Tb.Sp) were
analyzed on distal femurs, using Tri/3D-Bon software (Ratoc
System Engineering, Tokyo, Japan). Cortical bone volume,
cortical thickness, and center-line length were also analyzed
as previously described,(18) according to the guideline estab-
lished by the ASBMR.(19) To evaluate the topological differences
of the cross-sections, we calculated the ratios of the length on
the short axis (SA) versus the long axis (LA) at the diaphysis.
Skeletal preparation
Neonatal skeletons stained with Alcian Blue and Alizarin Red,
and stored in 80% glycerol in 0.2% KOH solution were
photographed essentially according to previously described
methods.(20)
Histological and histomorphometric analysis
Paraffin-embedded decalcified sections were stained with hema-
toxylin and eosin or toluidine blue-O (pH 4.5). To visulaize
osteoclasts, sections were stained with substrate for tartrate-
resistant acid phosphatase (TRAP). Bone resorption parameters
including osteoclast number/bone surface (Oc.N/BS) were ana-
lyzed based on the TRAP-positive multinucleated cells on distal
femoral sections.(18) For some samples, nondecalcified femurs and
skulls embedded in glycolmethacrylate (GMA)were sectioned and
stained. The analysis was based on the ASBMR guideline.(21)
Immunoblot analysis
Cultured cells were solubilized at each time point with SDS
sample buffer containing 62.5mM Tris-HCl (pH 6.8), 10%
glycerol, 5% 2-mercaptoethanol, and 2.25% SDS. The total cell
lysates were separated by SDS-polyacrylamide gel electropho-
resis and transferred to an Amersham Hybond-P PVDF
membrane (GE Healthcare, Piscataway, NJ, USA), which were
then treatedwith BlockingOne P (Nacalai, SanDiego, CA, USA) in
Tris-buffered saline containing Tween 20 for 60min. The
membranes were incubated with antibodies against Pfn1
(GeneTex, Irvine, CA, USA,) or GAPDH (14C10; Cell Signaling
Technology, Beverly, MA, USA), washed, and incubated with
horseradish peroxidase-labeled antirabbit IgG (GE Healthcare).
Band intensities were measured and analyzed using a LAS4000
imager with ImageQuant TL software (GE Healthcare).
Gene-expression analysis
Total RNA was isolated from bone marrow cells and RAW264.7
cells using the Trizol reagent (Thermo Fisher Scientific, Waltham,
MA, USA) according to the manufacturer’s protocol. Reverse
transcription (RT) was carried out using 1-mg total RNA.
Quantitative real-time PCR (qPCR) was carried out using StepOne
equipment (Applied Biosystems; Thermo Fisher Scientific). The
aliquots of 10-mL reagent mixture containing 2mL of cDNA
samples, 0.2mM forward and reverse primers, and 5mL of FAST
SYBR Green Master Mix (Applied Biosystems) were applied and
analyzed. Theprimer sequences for thePfn1were as follows: Pfn1-
forward, 5’-CCCCCACCGTTCCCTTTGGC-3’, Pfn1-reverse, 5’-
GCCCCCAGCCCATGTGGTTT-3’.
Cell culture
RAW264.7 cells were maintained in culture with Dulbecco’s
modified Eagle’s medium or alpha-MEM supplemented with
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10% FBS by subconfluent stage. By replating the cells onto
individual plates or wells, the osteoclastogenesis assay was
conducted using RANKL (100 ng/mL; Oriental Yeast Co., Tokyo,
Japan) as described previously.(18,22) The siRNA transfection was
conducted using lipofectamine RNAiMax reagent (Life Technol-
ogies; Thermo Fisher Scientific), according to themanufacturer’s
standard protocol. The siRNA for the mouse Pfn1 (Ambion
Silencer Select #4390771-s71525, Thermo Fisher Scientific;
Sense CAAUGGAUCUUCGUACCAATT, Antisense UUGGUAC-
GAAGAUCCAUUGTA) and control siRNA (Ambion Silencer
Negative Control No.1 siRNA) was purchased from the vendor
(Life Technologies; Thermo Fisher Scientific).
Bone marrow cells obtained from WT and Pfn1-cKO mouse
femurs and tibiaswere platedon100-mmplastic dishes at around
4 105 cells/cm2 in alpha-MEM supplemented with 10% FBS and
penicillin/streptomycin. After 4 hours of incubation at 37 °C, 5%
CO2, nonadherent bone marrow cells were replated on the assay
plates at 4 105 cells/cm2. For osteoclastogenesis assay, bone
marrow cells were cultured 48 hours in the presence of M-CSF
(10 ng/mL; R&D Systems, Minneapolis, MN, USA); then the
medium was changed to that containing both RANKL
(100ng/mL) and M-CSF. The osteoclast differentiation was
monitored usually for 5 days, by periodically changing the
medium. The osteoclast induction was also conducted by an
optimized method.(23,24) Bone marrow cells were cultured on a
60-mmplastic dish for 2 to 3 hours in alpha-MEM containing 10%
FBS. Nonadherent cells were reseeded in multiwell plates at
2.6 105 cells/cm2 and cultured for 24 hours in alpha-MEM with
10% FBS and 1:50 CMG14-12 culture supernatant containing M-
CSF. These cellswere cultured for 72 hourswithM-CSF andRANKL
(36 ng/mL). The cells were fixed and stained for TRAP activity. To
quantify the TRAP-positive multinucleated cells, microscopic
images of entire wells were captured in tiled array by semi-
automated microscope BZ-X710 (Keyence, Osaka, Japan).
Immunofluorescent analysis of cultured osteoclasts
To analyze the morphological features of the wild-type and Pfn1-
cKO osteoclasts, localization of the Pfn1 was detected by
immunofluorescence, using rabbit anti-Pfn1 antibodies (11680-1-
AP; Proteintech-Japan, Tokyo, and GTX102072; GeneTex, with
identical results) and goat antirabbit IgG Allexa 546 (Life
Technologies). Actin cytoskeleton and nuclei were visualized by
Allexa Fluor 488 phalloidin (Life Technologies) and Hoechst 33342
(Dojindo, Kumamoto, Japan), respectively, asdescribed inLinet al.(6)
Pit formation assay
RAW264.7 cells plated at 5 103 cells/cm2 on a BD Bio Coat
culture well (Osteologic System; BD Biosciences, Bedford, MA,
USA) were cultured for 3 days in the presence of RANKL (100 ng/
mL), then transfected with the siRNA against Pfn1 or negative
control for 24 hours (until day 4). The RANKL-containing (100 ng/
mL) medium was changed every other day until evaluation. The
observation was basically made at the end of day 5 (48 hours
after transfection), but some experiments were done following a
modified protocol with longer culture periods.
Bone marrow-derived macrophages plated on BD Bio Coat at
5.3 104 cells/cm2 were immediately transfected with siRNA. By
inducing the osteoclastogenesis with M-CSF and RANKL, the
observation was made usually at day 6 (150 hours after
transfection). Bone marrow cells from Pfn1-cKO and WT
littermates were plated at 8.3 105 cells/cm2. By inducing the
osteoclastogenesis with M-CSF and RANKL, the observation was
made at day 4 (96 hours after RANKL). For evaluation, the cells
were removed by acid treatment, and the size of the resorption
pits was analyzed using ImageJ software on the tiled phase-
contrast images captured by BZ-X710 (Keyence).
Live-cell imaging
RAW264.7 cells were plated on a 24-well plate at 1 104 cells/
well. After 24 hours, the cells were transfected with Pfn1- or
control-siRNA (Ambion; Thermo Fisher Scientific) using Lip-
ofectamine RNAiMax reagent and cultured for 6 hours. Then,
siRNAwas washed out, and the cells were incubatedwith RANKL
for 72 hours. Similarly, nonadherent bone-marrow-derived cells
(5 105 cells/well) plated on a 24-well plate were subjected to
the osteoclastogenesis assay as described above.(23) Live
imaging was conducted from 48 to 72 hours after adding
RANKL, using BioStation CT (Nikon, Melville, NY, USA). The
images were captured every 13min for RAW264.7 cells and
every 11min for bone marrow cells. The average distances and
the velocity at each interval were quantified using the manual
tracking and chemotaxis tool of the ImageJ software.
For live-cell imaging of the modified wound-healing assay,
RAW264.7 cells were plated on glass-bottom dishes (Matsunami,
Bellingham, WA, USA) at 1 105 cells/cm2 in the presence of
RANKL (100 ng/mL). To create a spotty wound on the bottom, a
cloning cylinder was placed on the bottom. After 72 hours, the
cells were transfected with Pfn1- or control-siRNA. At 4 to 5 days,
the cloning cylinders were removed to start live imaging using
the laser-scanning confocal microscope Fv-10i (Olympus, Tokyo,
Japan). Similarly, nonadherent bone-marrow derived cells
(1 106 cells/cm2) plated on the glass-bottom dishes with
cloning cylinders were subjected to osteoclastogenesis using
M-CSF (10 ng/mL) and RANKL (100 ng/mL). The cloning cylinders
were removed at approximately 2 days to start capturing the
images every 15min for 24 hours.
Statistical analysis
Statistical analysis was performed on the data obtained by
biological, histological, radiological, and physical measure-
ments. Normal distribution was tested by the Kolmogorov-
Smirnov (K-S) test, when applicable; the data were basically
represented by mean SD. The Student’s t test or the Mann-
Whitney test was applied to compare the two experimental
groups.
Results
Pfn1-KD affects osteoclast migration and matrix
resorption
Pfn1 was expressed in osteoclasts, and its intracellular localiza-
tion was detected by immunofluorescence (Supplemental
Fig. 1A). To examine its cellular functions, we knocked down
the Pfn1 mRNA in preosteoclastic RAW264.7 cells by siRNA
transfection: The KD efficiency at 24 hours was 47.3 2.52 % by
qPCR analysis. In osteoclastogenesis by standard protocol, we
found the number of TRAP-positive cells was comparable
between the Pfn1-KD cells and control cells, whereas their size
seemed to be slightly larger (Fig. 1A, B). However, detailed
analysis of their size distribution using fluorescent images did
not indicate significant differences between them (Supplemen-
tal Fig. 2B). We did detect increased locomotion of Pfn1-KD cells
compared with that of controls by live-cell imaging analysis
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(Fig. 1F, G and Supplemental Movie 1). Similar results were
obtained bymodified scratch-wound healing assay with live-cell
imaging (Supplemental Fig. 2C–E, Supplemental Movie 2). In
addition, pit formation assay revealed that Pfn1-KD cells tended
to resorb more mineralized matrix by larger pits with
comparable numbers per area (Fig. 1C, D; 48 hours after
transfection). The results suggest that the increased mobility of
each osteoclast may amplify matrix-resorbing activity. This is
consistent with a recent report showing that chemokine
pathways that activate RhoA and ROCK increase bone resorption
in culture without increasing the osteoclast number.(25) To test if
the Pfn1-KD osteoclasts are indeed more potent in bone
Fig. 1. Migration and matrix-resorption of the RAW264.7 cell-derived Pfn1-KD osteoclasts are increased. RAW264.7 cells transfected with siRNA as
negative control (siNT) or against Pfn1 (siPfn1)were subjected to the osteoclastogenesis using RANKL. (A) Multinucleated (n 3) TRAP-positive cells (Oc.
N) were counted in all wells. Six wells per experimental group were evaluated. (B) Pit formation assay was conducted on artificial mineralized matrix by
RAW264.7-derived osteoclasts. After 5 days of culture (48 hours after transfection), cells were lysed and the microscopic images were obtained (upper
panels). The traced images (bottom panels) were analyzed by ImageJ. N.S.¼not significant. Scale bars: 100mm. (C) Average pit size in area was analyzed
based on the traced images (C, bottom). (D) Live imaging analysis was performed for 24 hours on the osteoclastogenesis assay using siPfn1 transfected
RAW264.7 cells. Representative images at 24 hours after reseeding are shown with the trails of multinucleated cells. Bottom panels are the magnified
images for the boxed areas in the upper panels. (E) The average migration velocity, measured every 13min per cell, was compared between the control
and Pfn1-KD cells. Scale bars: 100mm. Error bars: SDs. Student’s t test was applied. p< 0.05.
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Fig. 2. Continued.
-%051 3OXV OSTEOCLAST REQUIRES PROFILIN 1 FOR SKELETAL MODELING 5OSTEOCLAST REQUIRES PROFILIN 1 OR SKELETAL MODE ING 35 of 14 :2$
resorption, we knocked down the Pfn1 on bone marrow cells. By
evaluating the pit formation after 6 days of osteoclast induction,
we found that the Pfn1-KD osteoclasts resorb more mineralized
matrix than those transfected with control siRNA (Supplemental
Fig. 1B–E).
Growth failure arises postneonatally in Pfn1-cKO mice
To investigate the roles of Pfn1 in osteoclasts in vivo, conditional
Pfn1-knockout (Pfn1-cKO) mice were generated by crossing the
Pfn1fl/fl and CatK-Cre knock-in mice (CatKCre/þ). When the Pfn1fl/fl
females were crossed with the CatKCre/þ; Pfn1fl/þ males or vice
versa, the prevalence of the Pfn1-cKO mice (Pfn1fl/fl; CatKCre/þ)
was approximately 25%. This natural segregation following the
Mendelian law indicated that osteoclastic Pfn1 is dispensable for
mouse embryogenesis. Neonatal skeletal preparation by Alizarin
Red and Alcian Blue staining indicated no apparent difference
between the Pfn1-cKO and control mice (Pfn1fl/fl; CatKþ/þ mice:
hereafter, described as WT; Supplemental Fig. 3).
However, at weaning, themutantmice tended to be smaller in
size, with a steeper nose than WT mice. The plain radiograms
and 3D mCT images at 4 weeks revealed deformed limb long
bones (Fig. 2A–E) and craniofacial bones (Fig. 2J). Morphometric
analysis on trabecular and cortical femurs did not indicate
significant differences, except for the shape of the diaphyseal
cross-sections at this age (Fig. 2F–I).
At 8 weeks, the skeletal phenotypes becamemore remarkable
with shortened body and femur length (Fig. 3A, E, H), as well as
skull and long bone deformities in Pfn1-cKO mice (Fig. 3B–H).
The shortened nose, maxilla, and distorted zygomatic arches
(Fig. 3B) could be the elements contributing to the altered facial
appearance with a steep nose-to-head curvature on their profile
(Fig. 3B).
Anterior cranial and facial bones were hypoplastic in Pfn1-cKO
mice as found by 3D mCT
To analyze the skull deformities more quantitatively, we utilized
the reconstructed 3D mCT images (Fig. 4A). The quantification
demonstrated a significant reduction of the midsagittal length of
the nasal bone in Pfn1-cKO mice compared with that of WT mice
(Fig. 4B; approximately 83% in male mice and 76% in female
mice). The frontal bone was also slightly shorter in the male Pfn1-
cKO mice (Fig. 4C; to approximately 91%), but temporal bones
were similar. By looking at the cranial bottom-side, the premaxilla
andmaxilla were remarkably hypoplastic (Fig. 4A, E), whereas the
sphenoidal andoccipital boneswereonlymoderately hypoplastic
(Fig. 4A, F, see also Supplemental Fig. 4D, E).
Interestingly, despite the longitudinal shortening of the
frontal bones, the lateral width was significantly broader in the
Pfn1-cKO mice (Supplemental Fig. 4A, B; approximately 108%
in male mice and 104% in female mice). Similarly, the
zygomatic arches were shortened and broadened (Fig. 4D
and Supplemental Fig. 4C). We assumed the findings could
indicate a mechanical weakness and imbalance among the
cranial bones. This assumption was also consistent with the
findings on lateral view of the reconstructed skull images: The
calvarial bone curvature was flattened anteriorly and convex
posteriorly, the facial bones, including the mandibula, were
smaller in Pfn1-cKO mice (Fig. 4G and Supplemental Fig. 4F, G).
Long bones in extremities represent the Erlenmeyer-flask deformity
with osteolytic appearance
Because the site-specific impairment of the cranial bone growth
tended to be limited in the structures developmentally requiring
chondrogenesis, we tested if there was a failure in cartilaginous
bone growth in Pfn1-cKOmice. However, despite the shortening
of the entire bone (Figs. 2 and 3), no obvious change was
detected in femoral and tibial growth-plate chondrocytes and
columnar structures in histological sections at 4 weeks (Supple-
mental Fig. 5) and 8 weeks (Fig. 5A, B). Instead, we noticed that
the curves of the growth plate tended to be flattened in the
Pfn1-cKO mice (this was confirmed by measurement; data not
shown), possibly because of the expansion of bone marrow
space. In parallel, they showed expanded distal femur
metaphysis representing the Erlenmeyer-flask deformity at
complete penetration at each stage, with the findings of
trabecular bone loss and expanded bone marrow cavity
(Figs. 2D–I and 5). These observations suggested that the
Pfn1-cKO skeletal deformity may be causally related to the
increased resorption of the bone nearby growing cartilaginous
structures. Indeed, the Erlenmeyer-flask deformity is usually
associated with osteolytic conditions in children, though
osteopetrotic conditions would also contribute to the
changes.(26) Thus, we analyzed if bone structures of Pfn1-cKO
mice at distal and midshaft femurs were consistent with this
notion, by using 2D projection and 3D reconstruction of mCT
images (Fig. 5C, D). The altered cross-sectional contour of the
metaphysis (Fig. 5C) and diaphyseal cortex (Fig. 5D) were
evident, where the Pfn1-cKO femurs represented a circular
shape, in contrast with the elliptical shape inWT femurs (Fig. 5D).
Significant differences were detected in the ratios of the SA
versus LA length (Fig. 5H; 0.79 0.015 versus 0.69 0.027 in
males, 0.80 0.026 versus 0.69 0.025 in females). In addition,
Fig. 2 Postnatal skeletal growth is impaired in the Pfn1-cKO mice at 4 weeks. (A) Representative plain radiograms of a male WT and the Pfn1-cKO
littermate at 4 weeks. Note that the mutant nose, the distal humerus, and the distal femurs (yellow arrows) are shorter than in WT mice. (B) Body
weight was compared in WT and Pfn1-cKO mice. (C) Body length (nose-rump length) measured on plain radiograms was compared in WT and Pfn1-
cKO mice. (D) Representative reconstructed 3D-mCT images of the femurs. Note that the mutant proximal femur (white arrow) is shorter than in WT
mice. Note also the altered shape of the distal femur (yellow arrows). Scale bars: 1mm. (E) Length of the femurs was measured based on the 3D
reconstructed mCT images represented by panel D. (F) Representative cross-sectional views of 3D mCT images of the diaphyseal femurs. Scale bars:
1mm. (G–I) Trabecular bone parameters of distal femurs were analyzed based on the 3D mCT analysis. BV/TV¼bone volume / tissue volume; Ct.
th¼ cortical thickness; SA¼ shorter axis; LA¼ longer axis of cross-sectional femoral diaphysis; N.S.¼not significant. (J) Differential facial appearance in
upper, bottom, and lateral views of WT and cKO skull were visualized by reconstructed 3D mCT images. Mutant nose is short and straight (yellow
arrows). Scale bar: 8mm. Error bars: SDs. The numbers of WT and Pfn1-cKO mice were 6 and 5, respectively. Statistical analysis was conducted by
Student’s t test. p< 0.05.
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the trabecular bone parameters indicated the osteopenic
conditions by lower BV/TV and Tb.th (Fig. 5C, E, F). The
paradoxical stability of the Tb.N, Tb.Sp, and Tb.Spac (Supple-
mental Table 1) could be because of the expanded trabecular
bone area in the mutant bones as indicated by cross-sectional
images (Fig. 5C). The cortical bone thickness at the diaphysis was
also significantly smaller in Pfn1-cKO femurs than in WT femurs
(Fig. 5G). Bone-forming activity of the osteoblast seemed not to
be so affected because the histomorphometric bone formation
parameters in preliminary samples did not show any clear
differences (data not shown). Therefore, the long-bone
deformity observed in the Pfn1-cKO mice must be based on
the osteolytic conditions in the metaphysis and diaphysis.
We then examined if the osteoclastic bone resorption was
indeed increased in the histological sections of Pfn1-cKO mice
(Fig. 6A). TRAP staining indicated that the number of
Fig. 3. Skeletal craniofacial and limb growth is impaired in the Pfn1-cKO mice. (A) Representative plain radiograms of a male WT and cKO littermate at
8weeks. (B) Differential facial appearancewas demonstrated by representative photo-images ofWT and cKOmice (upper panels). Magnified skull images
from panel A indicate the shortenedmaxilla and nose as well as deformed zygomatic arches (arrows). (C) Skeletal radiograms of panel Awere enlarged at
femurs (bottom panels) and humerus (upper panels). Differential appearances were pointed by yellow arrows. (D) Comparison of body weight inWT and
Pfn1-cKO mice. Yellow arrows point to differential appearances. (E) Comparison of body length (Nose-rump length) of WT and Pfn1-cKO mice. (F)
Representative 3D mCT images of the femurs. Scale bars: 4mm. (G) The length of distal humerus from deltoid process to the end was quantified on the
plain radiograms (as in panel C, upper panels). (H) Length of the femurswasmeasured based on the 3D reconstructedmCT images shown in panel F. Error
bars: SDs. The number of samples for the WT and Pfn1-cKO male and female were 15, 17, 12, and 14, respectively. Statistical analysis was conducted by
Student’s t test. p< 0.05.
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multinucleated osteoclasts was increased at the primary and
adjacent secondary trabecular surface of the Pfn1-cKO femurs
(Fig. 6B, D). More importantly, prominent numbers of multinu-
cleated TRAP-positive cells were detected in Pfn1-cKO mice at
the endosteal regions of the metaphysis to the diaphysis,
whereas the osteoclast distribution is usually rare in WT mice
(Fig. 6C, E). In contrast, a few number of periosteal osteoclasts
found in the WT metaphysis was absent in the Pfn1-cKO femurs,
possibly indicating the compensational protection against
periosteal remodeling. We assumed such an imbalance led to
the expanded metaphyseal deformity in the Pfn1-cKO mice.
The osteolytic changes were also detected by skull mCT,
especially the frontal and nasal bones with opened suture
(Fig. 6F). In histology, the suture in mutant mice was filled with
thick fibrocartilaginous tissues, whereas the suture in wild-type
mice was almost closed. Correspondingly, the internal surface of
the adjacent bones was strongly stained with residual TRAP
activity when overstained (Fig. 6F; bottom panel), and the
multinucleated TRAP-positive cells were increased (Fig. 6G;
plastic section). We assumed the excessive bone resorption may
have competed against the growth of ossifying fibrous suture in
this region.
Fig. 4. Facial bone- and cranial base-hypoplasia revealed by 3D mCT analysis of the Pfn1-cKO mouse skull. (A) Representative reconstructed 3D mCT
images of the WT and cKO skull were visualized by upper (left), bottom (intermediate), and lateral projections (right). Note that the anterior skull
including the maxilla and mandibula are hypoplastic in Pfn1-cKO mice. The cranial base was hypoplastic, and the zygomatic arches were deformed in
Pfn1-cKOmice. Scale bars: 10mm. (B–E) Length of major anatomical units was quantified three dimensionally, for the nasal bone length (B), frontal bone
length (C), zygomatic arch length (D), maxilla length (E), sphenoidal bone length (F), and mandible length (G). The landmarks utilized for the
measurements are indicated in Supplemental Fig. 2A, B, F,H. Error bars: SDs. Three randomly selected sampleswere utilized for themeasurements in each
group. Statistical analysis was conducted by Student’s t test. p < 0.05.
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Pfn1-deficiency enhances osteoclast migration with
slightly increased size
The increased osteoclast number in the metaphyseal endos-
teum of Pfn1-cKO femurs may suggest an increased
differentiation potential of preosteoclasts in bone marrow.
However, the osteoclastogenesis assay using Pfn1-cKO and WT
bone marrow cells indicated that the number of TRAP-positive
osteoclasts was identical in Pfn1-cKO andWT cultures (Fig. 7A, B).
Instead, we noticed the mutant osteoclasts were larger. A size-
Fig. 5. Long bones are deformed with osteolytic expansion. (A) Frontal section of the distal femurs at 8 weeks of age was compared using hematoxylin
and eosin staining. Despite the differences in the bone shape, no significant difference was detected in the growth plate. Right panels represent
magnified views of boxed areas in left panels. (B) Serial sectionwas stainedwith toluidine blue. No obvious difference in columnar structure of the growth
plate chondrocytes was detected (see also images of younger mice in Supplemental Fig. 4). (C–H) 3DmCT analysis was performed onWT and cKOmouse
femurs. Representative images for distal femur trabeculae (C) and cortical bone structure at midshaft (D) are shown. Trabecular bone volume at distal
femur (C) was quantified by bone volume/tissue volume (BV/TV; %) (E) and trabecular thickness (Tb.th; F). Cortical thickness (Ct.th) (G) was analyzed at
midshaft. The ratio of shorter axis versus longer axis of the cross-sectional cortex was compared (H). Scale bars: 200mm (A,B), and 1mm (C,D). Error bars:
SDs. Statistical analysis was conducted by Student’s t test. p< 0.05.
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distribution analysis of multinucleated osteoclasts using the
Mann-Whitney test indicated that the osteoclast size, in
addition to the total podosome-belt length, was significantly
larger in Pfn1-deficient cells (Fig. 7G–I). The slightly increased
osteoclast size may be related to the increased preosteoclast
movement increasing the chance of fusion. To verify the
increased movement of the Pfn1-cKO osteoclasts, the
locomotion of bone-marrow-derived Pfn1-cKO osteoclasts
was analyzed by live imaging (Fig. 7C). Although the number
of multinucleated cells was comparable between the WT and
Pfn1-cKO cells, the locomotive trails of the osteoclasts were
significantly increased in the Pfn1-cKO cells under this
condition (Fig. 8 and Supplemental Movie 3). Pit formation
assay indicated the increased matrix resorption by Pfn1-cKO
cells (Fig. 7D–F). Therefore, these results show, for the first
time, that Pfn1 has an essential role in the maintenance of
osteoclast movement, and hence for proper skeletal develop-
ment and homeostasis.
Fig. 6. TRAP-positive cells are increased at osteolytic expansion in limb long bones and cranial sutures. (A) Representative frontal sections of the distal
femur were stained with TRAP activity. The areas circled or boxed with dot-and-dashed lines were subjected to the analysis of the osteoclast number per
bone surface (Oc.N/BS; Fig. 6D, E). Solid boxes and dashed boxes were magnified in 6B, C. (B) Magnified images of TRAP-positive osteoclasts detected in
dashed boxes in 6A (metaphyseal secondary trabeculae). (C) Magnified images of TRAP-positive osteoclasts detected in solid boxes in 6A (endosteal bone
surface). (D) The Oc.N/BS was counted at the primary and secondary spongiosa under the growth plate as indicated by solid boxes in panel A. (E) The Oc.
N/BS was counted at the endosteal surface of themetaphysis as indicated by dot-and-dashed boxes in panel A. (F) Frontonasal suture of the WT and cKO
mice was analyzed by sagittal histological sections stained with hematoxylin and eosin (upper panels) and TRAP staining (bottom panels). See also the
mCT images (Figs. 2J and 4A) for suture expansion. (G) TRAP-positive osteoclasts were also visualized on GMA-embedded sagittal sections. Upper panels
are themagnified views of the boxed area in the bottom panels. Scale bars: 100mm in B and C, 200mm in F and G bottom, and 50mm in G top. Error bars:
SDs. Statistical analysis was conducted by Student’s t test. p< 0.05.
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Discussion
This study demonstrated that Pfn1 functions negatively in
osteoclast movement and bone-resorbing activity. A novel
aspect of Pfn1 function was also demonstrated by postnatal
growth failure in craniofacial and limb bones associated with an
osteolytic expansion in osteoclast-specific Pfn1-deficient mice.
Of note, the long bone deformity at metaphysis resembled the
Erlenmeyer-flask deformity that is known to be associated with
several human disorders that result from dysregulated bone
Fig. 7. Continued.
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turnover during the growth phase.(26) Although the exact
molecular events altering the Pfn1-deficient osteoclasts were
not thoroughly defined in the current study, our study clearly
indicates that the enhanced osteoclast movement based on
altered cytoskeletal regulation resulted in an osteolytic
Erlenmeyer-flask deformity. Our findings provide a novel
understanding of osteoclast function and related bone defor-
mities, including the Erlenmeyer-flask deformity.
The increased osteoclast movement observed in our Pfn1-cKO
mice is consistent with a recent theory that Pfn1 functions
negatively in the assembly of branched actin networks required
for the formation of lamellipodia and podosomes.(11–13) Our
findings are also consistent with previous reports suggesting a
suppressive role for profilins on lamellipodia and invadopodia in
cancer cells, contributing to their invasive features.(14,15,27) The
molecular mechanisms of how the profilins work in both
enhancing and inhibiting cell movement still remain un-
clear.(11–13) The classical understanding of the profilins is that
profilins support the formin-bound barbed-end elongation of
the actin filaments by efficiently adding the ATP-bound actin
monomers.(28,29) This molecular feature assists elongation of the
nonbranched filopodial filaments contributing to mesenchymal
cell movement. Mesenchymal cell movement is basically
supported by Pfn1 in most situations. However, the different
processes, namely the lamellipodia and podosomes, are
structured mainly with branched filamentous net-
works.(11–13,30,31) For these structures, the elongation relies on
different molecules, including Ena/Vasp and Arp2/3, which have
been shown to be inhibited by Pfn1.(11–13) Thus, our observation
provides another example of this inhibition by Pfn1. Osteoclast
movements have been suggested to rely on this suppression by
Pfn1. Interestingly, a recent study has found that cofilin, an actin-
binding protein that interacts with cortactin, is required for
osteoclast podosome patterning.(32) Pfn1 has been reported to
be a binding factor for cortactin, whichmediates smoothmuscle
contraction.(33) Hence, it would be interesting to investigate if
Pfn1 also exerts its interactive functions in the podosomes of the
osteoclasts.
A study of how increased osteoclast movement could
enhance osteolysis at the endosteal metaphysis and diaphysis
in Pfn1-cKO mice would also be of worth. In our cell culture
experiments, the number of osteoclasts was not increased in
contrast to the increased osteoclasts detected in vivo. In
addition, only a slight increment was found in the size of the
osteoclasts derived from RAW264.7 cells and bone marrow cells,
which could be associated with increased migration theoreti-
cally by increasing the chance to fuse. Presumably, such an effect
could be masked in culture conditions because their chance to
meet the right fusion partners might be enhanced in culture
conditions as compared with in vivo conditions. In another
possibility, the locomotive function increased by the absence of
Pfn1 in osteoclasts may have made it possible to travel from the
initial site of osteoclastogenesis to distant areas that might have
promoted a longer life span (Fig. 8C). A recent live-cell imaging
study showed that moving osteoclasts are more potent in
resorbing bone matrix,(34) and may survive longer than resting
cells. Thus, our observations could be explained by the increased
endosteal bone resorption based on longer survival of more-
potent osteoclasts (Fig. 8C). Accelerated endosteal osteolysis
can be the cause of an expanded thinner bone collar. Periosteal
expansion, which contributes to the characteristic Erlenmeyer-
flask deformity, could be explained by periosteal osteoblast
compensation against mechanical impairment caused by
endosteal bone resorption: The increased periosteal bone
formation may have masked the periosteal osteoclasts in
Pfn1-cKO femurs that are usually found in WT femurs. Increased
endosteal bone resorption would also explain the abnormal
lateral broadening and impaired longitudinal growth of the
facial and cranial bones in Pfn1-cKOmice (Figs. 3I, 4A, and 6D–F).
The Erlenmeyer-flask deformity, a term describing a specific
abnormality of the distal femur, is a clinical sign of the
dysregulated long-bone remodeling during longitudinal
growth.(26) Although various skeletal disorders, including
osteopetrosis, could be associated with this abnormality, its
predominant cause is increased bone resorption.(26) The typical
group of associated syndromes includes osteopenic disorders
such as Engelmann disease and Melnick-Needles syndrome; the
unclassified group includes Gaucher disease and Nasu-Hakola
disease, whose characteristics include bone marrow expansion
and infiltration. Thus, the phenotypic feature of the Pfn1-cKO
mice could be regarded as typical Erlenmeyer-flask deformity
based on the increased bone resorption at metaphysis.(26) A
recent study has found that macrophages utilize the MT1-MMP
for the turnover of podosomes as well as invadopodias.(35) The
Mt1-mmp KO mice,(36) like Mmp2-deficient mice,(37) showed
osteolytic skeletal deformities resembling our Pfn1-cKO mice.
Because these mutant mice recapitulate the human disorder,
multicentric osteolysis nodulosis arthropathy (MONA),(38,39) it
might be of interest to investigate if the increased migration of
MT1-MMP-deficient osteoclasts contributes to the osteolytic
phenotype. Our Pfn1-cKO mice could be used to investigate the
pathogenesis of these related disorders. Our results also suggest
the importance of the osteoclastic cytoskeleton in the disorders
associated with Erlenmeyer-flask deformity.
Lastly, the causative mechanisms of the short stature of the
Pfn1-cKOmice were not defined in the present study. Despite an
Fig. 7 In vitro migration and maturation are enhanced in Pfn1-deficient preosteoclasts. (A) The osteoclastogenesis of WT and Pfn1-cKO bone marrow
cells was evaluated by TRAP staining. Scale bar: 500mm. (B) Multinucleated TRAP-positive cells (Oc.N) were counted in all wells. Three wells per
experimental group were evaluated in this experiment. Identical results were confirmed by experiments repeated more than 3 times. N.S.¼not
significant. (C) Representative Phalloidin staining of the osteoclasts. Magnified images of the osteoclasts are shown in the bottom panels. Scale bar:
100mm. (D) Size of the cultured osteoclasts (OCL area; D) was quantified in the images represented by panel C. (E) Total podosome-belt/ring length
(ring length) was quantified similarly. (F) Pit formation assay was conducted using bone marrow cells derived from WT and Pfn1-cKO mice. After 5 days
of osteoclastogenesis on the plate, cells were lysed and the microscopic images were taken (upper panels). The images were analyzed on Image J
software (bottom panels). (G) Entire pit area represented by panel F was quantified per well (24-well plate) and compared in WT and Pfn1-cKO cells.
Error bars: SDs. Osteoclast number (B) and pit area (G) were statistically analyzed by Student’s t test. Other parameters (D and E) were analyzed by
Mann-Whitney test. p< 0.05, p< 0.01.
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apparent growth failure in proximal limb bones and the facial
bones, the only detectable histological findings were the
expanded distribution of the osteoclasts. In a previous study,
Yang et al reported that the CatK-Cre knock-in mice that we
utilized hereto delete the Pfn1-flox allele in osteoclasts had
aberrant periosteal Cre expression in the chondrogenic
progenitor cells, specifically at the groove of Ranvier.(40)
However, despite displaying altered growth plate curvature,
the chondrocytes in this region did not show any alteration in
the columnar alignment that we observed histologically in
chondrocyte-specific Pfn1-cKO mice in a previous study.(7) The
possible involvement of osteoblastic precursor cells and
osteocytes in this region was not thoroughly investigated, but
the absence of alterations in growth plate chondrocytes in dwarf
mice is not surprising because this is often the case in the
dysplastic mutant mice and human disorders associated with
impaired bone turnover and short stature.(41,42) Short stature in
osteopetrosis patients is a recurrent symptom, with no apparent
pathological changes in growth plates. Similarly, most patients
with osteodysplastic disorders—especially associated with
Erlenmeyer-flask deformity—are short in stature with no specific
growth-plate abnormalities. Melnick-Needles syndrome is
caused by the recurrent point mutations clustered at exon 22
of the filamin A gene (FLNA), one of the actin filament-binding
proteins.(43) Therefore, whether the alteration of cytoskeletal
protein functions in osteoclasts leads to growth failure in various
mutant alleles in the conditional gene KO mice would be an
interesting line of investigation.
In summary, we investigated the osteoclast-specific functions of
Pfn1 in mice and in cultured osteoclasts, and revealed its inhibitory
function on osteoclast movement. The increased migration of
osteoclasts because of Pfn1 deficiency resulted in an expansion of
endosteal bone resorption at the metaphysis and diaphysis,
leading to Erlenmeyer-flask deformity. Our study explored a novel
aspect of the molecular mechanisms that contribute to the
pathogenesis of various skeletal disorders, which may lead to a
better understanding and treatment of such disorders.
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